<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>84(3)</volume><submitter>Schlotelburg W</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>We aimed to evaluate the prognostic potential of baseline [&lt;sup>18&lt;/sup>F]FDG PET/CT for overall survival (OS) in patients with adrenocortical carcinoma (ACC).&lt;h4>Methods&lt;/h4>We performed a retrospective analysis of 67 treatment-naïve ACC patients with available [&lt;sup>18&lt;/sup>F]FDG PET/CT at time of initial diagnosis. Pretherapeutic PETs of primary tumors were manually segmented and quantitative parameters (maximum/mean/peak standardized uptake value (SUV&lt;sub>max/mean/peak&lt;/sub>), metabolic tumor volume (MTV) and tumor lesion glycolysis (TLG, defined as TV*SUV&lt;sub>mean&lt;/sub>) were derived. Based on a visual read, absence (M0) or presence of metastatic disease (M1) were evaluated. Kaplan-Meier and Cox regression analyses were used to determine the prognostic value of the above mentioned markers on overall survival adjusted for established prognostic markers.&lt;h4>Results&lt;/h4>24/67 patients (36%) presented with M0 based on PET/CT, while the remaining 43/67 (64%) had M1-status. 32/67 patients died during follow-up and median OS was 48 months. In 12% of patients FDG-PET detected additional metastatic lesion not clearly visible by CT only. In univariable analysis, all quantitatively derived PET parameters failed to reach significance (P ≥ 0.1), and only PET/CT-based M1-status and Ki-67 were associated with increased mortality (M1: HR 13.89, 95% CI 4.15-86.32, P &lt; 0.001; Ki-67 HR 1.29, 95% CI 1.16-1.42; P &lt; 0.0001). Using multivariable Cox regression analyses, M1-status (HR 9.69, 95% CI 2.82-60.99) and Ki-67 index (HR 1.29, 95% CI 1.13-1.04; P &lt; 0.05) remained significant associated with OS.&lt;h4>Conclusion&lt;/h4>In treatment-naïve ACC patients, the quantitative PET parameter failed to predict OS, but presence of metastases detected by [&lt;sup>18&lt;/sup>F]FDG PET/CT and Ki-67 index were independently associated with shorter OS. Therefore, a simple visual PET-based read-out is of prognostic value at initial diagnosis, while time-consuming PET-based quantification can be omitted.</pubmed_abstract><journal>Endocrine</journal><pagination>1172-1181</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11208261</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma.</pubmed_title><pmcid>PMC11208261</pmcid><pubmed_authors>Schlotelburg W</pubmed_authors><pubmed_authors>Schirbel A</pubmed_authors><pubmed_authors>Fuss CT</pubmed_authors><pubmed_authors>Fassnacht M</pubmed_authors><pubmed_authors>Buck AK</pubmed_authors><pubmed_authors>Hahner S</pubmed_authors><pubmed_authors>Serfling SE</pubmed_authors><pubmed_authors>Hartrampf PE</pubmed_authors><pubmed_authors>Kosmala A</pubmed_authors><pubmed_authors>Kircher S</pubmed_authors><pubmed_authors>Werner RA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma.</name><description>&lt;h4>Purpose&lt;/h4>We aimed to evaluate the prognostic potential of baseline [&lt;sup>18&lt;/sup>F]FDG PET/CT for overall survival (OS) in patients with adrenocortical carcinoma (ACC).&lt;h4>Methods&lt;/h4>We performed a retrospective analysis of 67 treatment-naïve ACC patients with available [&lt;sup>18&lt;/sup>F]FDG PET/CT at time of initial diagnosis. Pretherapeutic PETs of primary tumors were manually segmented and quantitative parameters (maximum/mean/peak standardized uptake value (SUV&lt;sub>max/mean/peak&lt;/sub>), metabolic tumor volume (MTV) and tumor lesion glycolysis (TLG, defined as TV*SUV&lt;sub>mean&lt;/sub>) were derived. Based on a visual read, absence (M0) or presence of metastatic disease (M1) were evaluated. Kaplan-Meier and Cox regression analyses were used to determine the prognostic value of the above mentioned markers on overall survival adjusted for established prognostic markers.&lt;h4>Results&lt;/h4>24/67 patients (36%) presented with M0 based on PET/CT, while the remaining 43/67 (64%) had M1-status. 32/67 patients died during follow-up and median OS was 48 months. In 12% of patients FDG-PET detected additional metastatic lesion not clearly visible by CT only. In univariable analysis, all quantitatively derived PET parameters failed to reach significance (P ≥ 0.1), and only PET/CT-based M1-status and Ki-67 were associated with increased mortality (M1: HR 13.89, 95% CI 4.15-86.32, P &lt; 0.001; Ki-67 HR 1.29, 95% CI 1.16-1.42; P &lt; 0.0001). Using multivariable Cox regression analyses, M1-status (HR 9.69, 95% CI 2.82-60.99) and Ki-67 index (HR 1.29, 95% CI 1.13-1.04; P &lt; 0.05) remained significant associated with OS.&lt;h4>Conclusion&lt;/h4>In treatment-naïve ACC patients, the quantitative PET parameter failed to predict OS, but presence of metastases detected by [&lt;sup>18&lt;/sup>F]FDG PET/CT and Ki-67 index were independently associated with shorter OS. Therefore, a simple visual PET-based read-out is of prognostic value at initial diagnosis, while time-consuming PET-based quantification can be omitted.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2025-04-21T20:16:01.039Z</modification><creation>2025-04-05T17:58:30.756Z</creation></dates><accession>S-EPMC11208261</accession><cross_references><pubmed>38381353</pubmed><doi>10.1007/s12020-024-03695-6</doi></cross_references></HashMap>